Clinical usefulness of a supplementary cyclosporin administration with a topical application of maxacalcitol ointment for patients with moderate psoriasis vulgaris

Abe, Masatoshi; Syuto, Tomoko; Hasegawa, Michiko; Yokoyama, Yoko; Ishikawa, Osamu

doi:10.1111/j.1346-8138.2009.00623.x

Cited by 3 publications

(5 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The speed of its action on psoriatic lesions is rather slow, but the lack of side‐effects such as skin atrophy and induction of telangiectasia favors its long‐term use. Topical vitamin D3 treatment is used as monotherapy, as combination therapy with topical corticosteroids, or with narrowband ultraviolet B therapy, cyclosporin, etretinate or methotrexate …”

Section: Discussionmentioning

confidence: 99%

“…However, we also experience the usefulness of the additive effect of topical treatment for residual recalcitrant lesions that do not respond well enough to biologics. The additive effect of topical therapy to systemic therapy such as cyclosporin has been reported; however, the effect of topical treatment when combined with biologics has not been sufficiently investigated thus far.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Effects of maxacalcitol ointment on skin lesions in patients with psoriasis receiving treatment with adalimumab

Karakawa

Komine

Kishimoto

et al. 2016

The Journal of Dermatology

View full text Add to dashboard Cite

Adalimumab is a biologic that is very effective for treatment of psoriasis. However, recalcitrant or recurrent lesions sometimes occur during treatment. Maxacalcitol is an active vitamin D3 ointment that is effective in treatment of psoriasis. Topical therapy may be beneficial in treatment of recalcitrant or recurrent lesions during treatment with systemic therapy, but there is little evidence on this topic. We investigated the effect of maxacalcitol on skin lesions during treatment with adalimumab in patients with psoriasis. Twelve patients with psoriasis were randomly assigned to two groups after informed consent - treatment with adalimumab only (n = 6), and treatment with adalimumab and maxacalcitol (n = 6) - and they were evaluated every 4 weeks for 44 weeks. Exacerbation was defined as an increase of the Psoriasis Area and Severity Index (PASI) score. The interval between adalimumab treatments was elongated to 3-4 weeks from 2 weeks according to the individual patient's condition. The PASI score was evaluated every 4 weeks, and the frequency of exacerbations was counted. The overall improvement in PASI score was not statistically different between the two groups, but the frequency of exacerbations was significantly less in the maxacalcitol combination group compared with the adalimumab monotherapy group (Mann-Whitney U-test, P < 0.05). The better control of skin lesions in patients who elongated the interval of adalimumab administration was achieved in the maxacalcitol combination group compared with the adalimumab monotherapy group. Topical maxacalcitol treatment is effective and useful in controlling skin lesions in patients with psoriasis when used in combination with adalimumab.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Effects of maxacalcitol ointment on skin lesions in patients with psoriasis receiving treatment with adalimumab

Karakawa

Komine

Kishimoto

et al. 2016

The Journal of Dermatology

View full text Add to dashboard Cite

show abstract

“…Other frequently reported definitions were BSA‐increase >50% of baseline BSA ( n = 7), need for treatment ( n = 6), new lesions or exacerbation of existing lesions ( n = 3), and increase in BSA ≥ 10% ( n = 3). Two studies classified remission duration as short (<6 months), moderate (6–12 months), and long (>12 months) 21,22 …”

Section: Resultsmentioning

confidence: 99%

“…Two studies classified remission duration as short (<6 months), moderate (6-12 months), and long (>12 months). 21,22 Definitions for partial psoriasis remission…”

Section: Definitions For Duration Of Psoriasis Remissionmentioning

confidence: 99%

Definitions of remission in psoriasis: a systematic literature review from the National Psoriasis Foundation

Balak

Pérez-Chada

Guo

et al. 2022

Acad Dermatol Venereol

View full text Add to dashboard Cite

Psoriasis studies increasingly employ outcomes that indicate complete disease resolution, yet remission and cure are poorly defined for psoriasis. We conducted a systematic literature review to identify definitions of psoriasis remission and cure reported in the literature. Medline, EMBASE, and The Cochrane Central Register of Controlled Trials databases were searched on July 22, 2020, for full-text studies providing definitions for psoriasis remission/cure. Definitions were analysed descriptively for endpoint, time-frame, on/off treatment, patient-reported outcomes, and disease domains. We identified 106 studies that provided 41 unique remission definitions. Most definitions included endpoints based on Psoriasis Area and Severity Index (PASI), such as PASI75 (n = 16 studies), PASI90 (n = 10), PASI100 (n = 10), and PASI of 0 (n = 3), and descriptive endpoints related to 'skin clearance' (n = 18). Few definitions specified time-frame, on/off treatment or other psoriasis-related disease domains. One small consensus-initiative defined drug-free remission for plaque psoriasis by BSA of 0 without any therapy for at least 12 months. While there is no cure for psoriasis, seven studies defined psoriasis cure using similar endpoints to those used to define remission. We identified a variety of definitions of psoriasis remission. These results will inform the development of consensus-based definitions for psoriasis remission to support efforts to improve research and clinical outcomes.

show abstract

“…A synthetic analogue of vitamin D3 (1 alpha, 25-dihydroxy-22-oxacalcitriol), maxacalcitol is available as ointment (0.0025%); it is used in the treatment of psoriasis as monotherapy, as an adjuvant therapy with NB-UVB phototherapy [ 87 ], or with cyclosporine A (Cys A), particularly in order to maintain remission [ 88 ].…”

Section: Miscellaneous Agentsmentioning

confidence: 99%

Nonsteroidal Topical Immunomodulators in Allergology and Dermatology

Jovanović

Golušin

2016

BioMed Research International

View full text Add to dashboard Cite

The purpose of this study was to review currently available literature data concerning pathomechanisms of action, indications, treatment efficacy, as well as side effects of nonsteroidal immunomodulators used in dermatology, primarily for the treatment of allergic dermatoses. MEDLINE search was undertaken using the key words “Topical Immunomodulators, Dermatology and Allergy”. Full articles, and nothing but full articles, were used.

show abstract

Clinical usefulness of a supplementary cyclosporin administration with a topical application of maxacalcitol ointment for patients with moderate psoriasis vulgaris

Cited by 3 publications

References 17 publications

Effects of maxacalcitol ointment on skin lesions in patients with psoriasis receiving treatment with adalimumab

Effects of maxacalcitol ointment on skin lesions in patients with psoriasis receiving treatment with adalimumab

Definitions of remission in psoriasis: a systematic literature review from the National Psoriasis Foundation

Nonsteroidal Topical Immunomodulators in Allergology and Dermatology

Contact Info

Product

Resources

About